Abnormal prostaglandin E2 production blocks myogenic differentiation in myotonic dystrophy

Neurobiology of Disease

Volumn 45, Issue 1, 2012, Pages 122-129

  Beaulieu, Daniel ^a   Thebault, Philippe ^a   Pelletier, Richard ^a   Chapdelaine, Pierre ^a   Tarnopolsky, Mark ^b   Furling, Denis ^c   Puymirat, Jack ^a  

^a LAVAL UNIVERSITY   (Canada)

^b MCMASTER UNIVERSITY MEDICAL CENTRE   (Canada)

^c SORBONNE UNIVERSITÉ   (France)

Author keywords

Aspirin; CDM1; Cyclooxygenase; Differentiation; Muscle growth; Muscle satellite cell; Myoblast fusion; Myotonic dystrophy; Prostaglandin E2

Indexed keywords

ACETYLSALICYLIC ACID; CALCIUM; CYCLOOXYGENASE 2; PROSTAGLANDIN E RECEPTOR 2; PROSTAGLANDIN E RECEPTOR 4; PROSTAGLANDIN E SYNTHASE 1; PROSTAGLANDIN E2; PROSTAGLANDIN F2;

ARTICLE; AUTOCRINE EFFECT; CALCIUM CELL LEVEL; CELL DIFFERENTIATION; CONTROLLED STUDY; CTG REPEAT EXPANSION; DNA STRUCTURE; DRUG MECHANISM; ENZYME REGULATION; GENOME SIZE; HUMAN; HUMAN CELL; MITOSIS INHIBITION; MUSCLE DEVELOPMENT; MYOBLAST; MYOTONIC DYSTROPHY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROSTAGLANDIN RELEASE; PROSTAGLANDIN SYNTHESIS; PROTEIN SECRETION; SKELETAL MUSCLE SATELLITE CELL; TRINUCLEOTIDE REPEAT; UPREGULATION;

ASPIRIN; CALCIUM; CELL DIFFERENTIATION; CELLS, CULTURED; CYCLOOXYGENASE INHIBITORS; DINOPROSTONE; HUMANS; MYOTONIC DYSTROPHY; SATELLITE CELLS, SKELETAL MUSCLE; TRINUCLEOTIDE REPEAT EXPANSION; UP-REGULATION;

EID: 81955167953     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2011.06.014     Document Type: Article

References (36)

1. Asselin E., Fortier M.A. Influence of thrombin on proliferation and prostaglandin production in cultured bovine endometrial cells. J. Cell. Physiol. 1996, 168:600-607.
2. Barnett M.E., Madgwick D.K., Takemoto D.J. Protein kinase C as a stress sensor. Cell. Signal. 2007, 19:1820-1829.
3. Brook J.D., McCurrach M.E., Harley H.G., Buckler A.J., Church D., Aburatani H., Hunter K., Stanton V.P., Thirion J.P., Hudson T., et al. Molecular basis of myotonic dystrophy: expansion of a trinucleotide (CTG) repeat at the 3' end of a transcript encoding a protein kinase family member. Cell 1992, 68:799-808.
4. Entwistle A., Curtis D.H., Zalin R.J. Myoblast fusion is regulated by a prostanoid of the one series independently of a rise in cyclic AMP. J. Cell. Biol. 1986, 103:857-866.
5. Farkas-Bargeton E., Barbet J.P., Dancea S., Wehrle R., Checouri A., Dulac O. Immaturity of muscle fibers in the congenital form of myotonic dystrophy: its consequences and its origin. J. Neurol. Sci. 1988, 83:145-159.
6. Fu Y.H., Pizzuti A., Fenwick R.G., King J., Rajnarayan S., Dunne P.W., Dubel J., Nasser G.A., Ashizawa T., de Jong P., et al. An unstable triplet repeat in a gene related to myotonic muscular dystrophy. Science 1992, 255:1256-1258.
7. Furling D., Coiffier L., Mouly V., Barbet J.P., St Guily J.L., Taneja K., Gourdon G., Junien C., Butler-Browne G.S. Defective satellite cells in congenital myotonic dystrophy. Hum. Mol. Genet. 2001, 10:2079-2087.
8. Furling D., Lemieux D., Taneja K., Puymirat J. Decreased levels of myotonic dystrophy protein kinase (DMPK) and delayed differentiation in human myotonic dystrophy myoblasts. Neuromuscul. Disord. 2001, 11:728-735.
9. Harper P.S. Myotonic Dystrophy 2001, W.B. Saunders, London, Philadelphia.
10. Horsley V., Pavlath G.K. Prostaglandin F2(alpha) stimulates growth of skeletal muscle cells via an NFATC2-dependent pathway. J. Cell. Biol. 2003, 161:111-118.
11. Ikezoe K., Nakamori M., Furuya H., Arahata H., Kanemoto S., Kimura T., Imaizumi K., Takahashi M.P., Sakoda S., Fujii N., Kira J. Endoplasmic reticulum stress in myotonic dystrophy type 1 muscle. Acta Neuropathol. 2007, 114:527-535.
12. Kuyumcu-Martinez N.M., Wang G.S., Cooper T.A. Increased steady-state levels of CUGBP1 in myotonic dystrophy 1 are due to PKC-mediated hyperphosphorylation. Mol. Cell. 2007, 28:68-78.
13. Liquori C.L., Ricker K., Moseley M.L., Jacobsen J.F., Kress W., Naylor S.L., Day J.W., Ranum L.P. Myotonic dystrophy type 2 caused by a CCTG expansion in intron 1 of ZNF9. Science 2001, 293:864-867.
14. Loro E., Rinaldi F., Malena A., Masiero E., Novelli G., Angelini C., Romeo V., Sandri M., Botta A., Vergani L. Normal myogenesis and increased apoptosis in myotonic dystrophy type-1 muscle cells. Cell Death Differ. 2010, 17:1315-1324.
15. Mahadevan M., Tsilfidis C., Sabourin L., Shutler G., Amemiya C., Jansen G., Neville C., Narang M., Barcelo J., O'Hoy K., et al. Myotonic dystrophy mutation: an unstable CTG repeat in the 3' untranslated region of the gene. Science 1992, 255:1253-1255.
16. Murakami M., Kudo I. Recent advances in molecular biology and physiology of the prostaglandin E2-biosynthetic pathway. Prog. Lipid Res. 2004, 43:3-35.
17. Park J.Y., Pillinger M.H., Abramson S.B. Prostaglandin E2 synthesis and secretion: the role of PGE2 synthases. Clin. Immunol. 2006, 119:229-240.
18. Pelletier R., Hamel F., Beaulieu D., Patry L., Haineault C., Tarnopolsky M., Schoser B., Puymirat J. Absence of a differentiation defect in muscle satellite cells from DM2 patients. Neurobiol. Dis. 2009, 36:181-190.
19. Prisk V., Huard J. Muscle injuries and repair: the role of prostaglandins and inflammation. Histol. Histopathol. 2003, 18:1243-1256.
20. Ranum L.P., Cooper T.A. RNA-mediated neuromuscular disorders. Annu. Rev. Neurosci. 2006, 29:259-277.
21. Rossi M.J., Clark M.A., Steiner S.M. Possible role of prostaglandins in the regulation of mouse myoblasts. J. Cell. Physiol. 1989, 141:142-147.
22. Sarnat H.B., Silbert S.W. Maturational arrest of fetal muscle in neonatal myotonic dystrophy. A pathologic study of four cases. Arch. Neurol. 1976, 33:466-474.
23. 2+ concentration in nutritional medium. Exp. Cell Res. 1969, 58:163-167.
24. Shen W., Prisk V., Li Y., Foster W., Huard J. Inhibited skeletal muscle healing in cyclooxygenase-2 gene-deficient mice: the role of PGE2 and PGF2alpha. J. Appl. Physiol. 2006, 101:1215-1221.
25. Siciliano G., Pasquali L., Rocchi A., Falorni M., Galluzzi F., Rocco A., Malvaldi G., Pompella A., Paolicchi A. Advanced oxidation protein products in serum of patients with myotonic disease type I: association with serum gamma-glutamyltransferase and disease severity. Clin. Chem. Lab. Med. 2005, 43:745-747.
26. Sugimoto Y., Narumiya S. Prostaglandin E receptors. J. Biol. Chem. 2007, 282:11613-11617.
27. Tai H.H., Ensor C.M., Tong M., Zhou H., Yan F. Prostaglandin catabolizing enzymes. Prostaglandins Other Lipid Mediat. 2002, 68-69:483-493.
28. Timchenko N.A., Iakova P., Cai Z.J., Smith J.R., Timchenko L.T. Molecular basis for impaired muscle differentiation in myotonic dystrophy. Mol. Cell. Biol. 2001, 21:6927-6938.
29. Timchenko N.A., Patel R., Iakova P., Cai Z.J., Quan L., Timchenko L.T. Overexpression of CUG triplet repeat-binding protein, CUGBP1, in mice inhibits myogenesis. J. Biol. Chem. 2004, 279:13129-13139.
30. Toscano A., Messina S., Campo G.M., Di Leo R., Musumeci O., Rodolico C., Aguennouz M., Annesi G., Messina C., Vita G. Oxidative stress in myotonic dystrophy type 1. Free. Radic. Res. 2005, 39:771-776.
31. Usuki F., Ishiura S. Expanded CTG repeats in myotonin protein kinase increase susceptibility to oxidative stress. Neuroreport 1998, 9:2291-2296.
32. Usuki F., Takahashi N., Sasagawa N., Ishiura S. Differential signaling pathways following oxidative stress in mutant myotonin protein kinase cDNA-transfected C2C12 cell lines. Biochem. Biophys. Res. Commun. 2000, 267:739-743.
33. Vane J.R., Botting R.M. The mechanism of action of aspirin. Thromb. Res. 2003, 110:255-258.
34. Wheeler T.M. Myotonic dystrophy: therapeutic strategies for the future. Neurotherapeutics 2008, 5:592-600.
35. Wheeler T., Thorton C.A. Myotonic dystrophy: RNA-mediated muscle disease. Curr. Opi. Neurology. 2007, 20:572-576.
36. Wheeler T.M., Lueck J.D., Swanson M.S., Dirksen R.T., Thornton C.A. Correction of ClC-1 splicing eliminates chloride channelopathy and myotonia in mouse models of myotonic dystrophy. J. Clin. Invest. 2007, 117:3952-3957.